Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [¹⁸F]FDG in gynaecological malignancies: systematic literature review and meta-analysis.

ABSTRACT:

Purpose

This study aims to systematically review and perform a meta-analysis to compare the diagnostic performance of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) in gynaecological cancers.

Methods

A comprehensive search of PubMed/MEDLINE and EMBASE was conducted and updated to October 25, 2024, to identify clinical studies evaluating FAPI and [¹⁸F]FDG PET/CT or PET/MR in patients with gynaecological cancer. Quality was assessed using the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies). Per-lesion pooled estimates of sensitivity, specificity, positive predictive value, and negative predictive value were calculated with 95% confidence intervals.

Results

SUBMITTER: Florit A 

PROVIDER: S-EPMC12397109 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature